CAMBRIDGE, UK - 29th June, 2008 - Antitope, a privately held biotechnology company, today announced a research agreement with Vascular Pharmaceuticals, Inc. for the generation of therapeutic antibodies for treatment of vascular disease. The agreement brings together Vascular Pharmaceuticals’ expertise in therapeutic antibody discovery and Antitope’s Composite Human AntibodyTM technology for engineering of fully-humanized antibodies.
